Figure 2.
Novel approaches for improving NK-cell–mediated targeting of myeloma cells. Bispecific killer cell engagers (BiKEs) are composed of 2 antibody fragments that recognize tumor antigens and NK-cell activation receptors, while trispecific killer cell engagers (TriKEs) also include a component such as IL-15 to further enhance NK-cell activation. Antibody-recruiting molecules (ARMs) contain a terminus that binds endogenous IgG antibodies and is linked to a second terminus that binds tumor antigen, thus leading to opsonization of tumor cells with endogenous IgG and resulting in NK-cell–mediated ADCC.

Novel approaches for improving NK-cell–mediated targeting of myeloma cells. Bispecific killer cell engagers (BiKEs) are composed of 2 antibody fragments that recognize tumor antigens and NK-cell activation receptors, while trispecific killer cell engagers (TriKEs) also include a component such as IL-15 to further enhance NK-cell activation. Antibody-recruiting molecules (ARMs) contain a terminus that binds endogenous IgG antibodies and is linked to a second terminus that binds tumor antigen, thus leading to opsonization of tumor cells with endogenous IgG and resulting in NK-cell–mediated ADCC.

Created with BioRender.com

Close Modal

or Create an Account

Close Modal
Close Modal